ZyVersa Therapeutics executes 1-for-10 reverse stock split effective April 25, 2024

ZyVersa Therapeutics, Inc.

Reverse split ratio 1-for-10; approved by stockholders at special meeting on April 17, 2024.
Effective at 4:01 p.m. ET on April 25; split-adjusted trading begins April 26 on Nasdaq.
Par value unchanged; new CUSIP number is 98987D 300.
Common stock continues trading under symbol ZVSA on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ZyVersa Therapeutics, Inc.: Filed a certificate of amendment to effect a 1-for-10 reverse stock split of common stock (effective 2024-04-25).

Change: charter amendment
Effective: 2024-04-25

Exact text from the filing

On April 25, 2024, ZyVersa Therapeutics, Inc. (the "Company") filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware relating to a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”). The Reverse Stock Split became effective on April 25, 2024 at 4:01 p.m., and the Common Stock is expected to begin trading on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on April 26, 2024 at market open.

View on SEC.gov

263 governance changes filed in the last 30 days. Browse all governance changes →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-015938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.